Company Overview
| Stock Name | Venus Medtech-B |
|---|---|
| Stock Code | 02500 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 按二零一八年植入量計,為中國領先的經導管心臟瓣膜醫療器械企業,主要從事經導管心臟瓣膜產品的設計、開發及商業化,產品涵蓋主動脈瓣、肺動脈瓣、二尖瓣及三尖瓣的經導管解決方案及主要配套產品。 |
| Listing Date | 2019-12-10 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | 18A生物科技 |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國杭州濱江區江陵路88號2幢3樓311室 |
| Business Address (Hong Kong) | 香港灣仔皇后大道東248號陽光中心40樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | www.venusmedtech.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 33.00 / shares |
| Offer Price Range | To be extracted |
| Lot Size | 500 shares |
| Entry Threshold | To be extracted |
| Par Value | RMB 1.0 / shares |
| Offer Period | 2019-11-28 to 2019-12-03 |
| Global Offering Shares | 78,537,500 shares |
| HK Public Offer Shares (Initial) | 7,854,000 shares (10.0%) |
| Public Offer Lots (Initial) | 15,708lots (Pool A7,854lots,Pool B7,854lots) |
| International Placing Shares (Initial) | 70,683,500 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 392,688,443 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 39.3% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 2,591,737,500 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| Avg Daily HK Mkt Cap | HK$ 694.9M |
| Est. Threshold | HK$ 9.71B |
| Analysis Result | HK market cap below threshold, need +1298% |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | 不適用(公司處於虧損狀態) |
| Profit/Loss Status | 虧損人民幣300.5百萬元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
USD
Income Statement
| Item | 2017 | 2018 |
|---|---|---|
| Other income and gains, net | 0 | 76 |
| Selling and distribution expenses | -1,764 | -1,625 |
| Administrative expenses | -3,042 | -7,070 |
| Net finance costs | -676 | -945 |
| Profit before tax | -19,261 | -22,601 |
| Income tax expense | -37 | -144 |
| Profit for the year | -19,298 | -22,745 |
| Profit attributable to owners | -19,298 | -22,745 |
Balance Sheet
| Item | 2017 | 2018 | 2019-05 |
|---|---|---|---|
| Cash and cash equivalents | 1,145 | 7,279 | |
| Inventories | 0 | 0 | |
| Total current assets | 1,497 | 7,607 | |
| Total current liabilities | 4,458 | 9,332 | |
| Total equity | -5,960 | -812 | |
| Equity attributable to owners | -5,960 | -812 | |
| Interest-bearing borrowings | 5,220 | 0 | 0 |
Cash Flow Statement
| Item | 2017 | 2018-05 | 2018 | 2019-05 |
|---|---|---|---|---|
| Net cash from operating activities | -16,158 | -14,093 | ||
| Net cash from investing activities | -115 | -30 | ||
| Net cash from financing activities | 8,999 | 20,257 | ||
| Net increase in cash | -7,274 | 6,134 | ||
| Depreciation of PP&E | 93 | 28 | 70 | 19 |
| Depreciation of right-of-use assets | 210 | 85 | 210 | 100 |
| Purchase of PP&E | -115 | 0 | -30 | -23 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 43.05 |
|---|---|
| First Day Open | HK$ 40.0 |
| First Day Change | 30.45% |
| First Day Volume | 53035200.0 |
| First Day Turnover | 2107270000.0 |
| Use of Proceeds | 1、35.0%或約843.9百萬港元分配至我們的核心產品;
2、30.0%或約723.3百萬港元分配至我們的其他產品及在研產品;
3、10.0%所得款項凈額或約241.1百萬港元,為有關收購Keystone的代價付款及其他交易開支提供資金;
4、15.0%所得款項凈額或約361.7百萬港元,為我們透過內部研究及/或潛在收購持續擴充產品組合提供資金;
5、10.0%所得款項凈額或約241.1百萬港元,作營運資金及其他一般企業用途。 |
Underwriting Syndicate
Joint Sponsors (4)
Overall Coordinators (6)
Joint Bookrunners (9)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536
CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894
Credit Suisse (Hong Kong) Limited CE AAO017
CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650
招银国际融资有限公司 CE AVM940
海通国际证券有限公司 CE AAF806
BOCI ASIA LIMITED CE AET863
农银国际融资有限公司 CE AWL249
香港上海汇丰银行有限公司 CE AAA523
Joint Lead Managers (9)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536
CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894
Credit Suisse (Hong Kong) Limited CE AAO017
CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650
招银国际融资有限公司 CE AVM940
海通国际证券有限公司 CE AAF806
BOCI ASIA LIMITED CE AET863
农银国际证券有限公司 CE ACX411
香港上海汇丰银行有限公司 CE AAA523
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Aspex Master Fund | 156,519,000 HKD | — | 6.04% | — | 6 months | 2020-06-10 |
| 2 | Cephei QFII China Total Return Fund Ltd. | 156,519,000 HKD | — | 6.04% | — | 6 months | 2020-06-10 |
| 3 | China Alpha Funds | 78,259,500 HKD | — | 3.02% | — | 6 months | 2020-06-10 |
| 4 | GIC Private Limited | 234,778,500 HKD | — | 9.06% | — | 6 months | 2020-06-10 |
| 5 | Hillhouse Funds | 391,297,500 HKD | — | 15.10% | — | 6 months | 2020-06-10 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 曾敏 | — |
| Company Secretary | 馬海越、霍寶兒 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 訾先生實益擁有30,923,302股內資股(7.87%),另通過受控法團持有14,894,971股內資股(3.79%)及11,057,251股非上市外資股(2.82%);曾先生通過Horizon Binjiang LLC持有47,954,404股非上市外資股(12.21%)。Qiming相關實體合計持有30,342,501股H股(17.75%)及37,185,479股非上市外資股(16.77%)。 |
|---|




